Supplementary Figure 6 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Key Points
Prognostic stratification reveals insights into patient outcomes in metastatic urothelial cancer.
ctDNA and tissue assessments demonstrate a strong correlation with ECOG performance status, aiding treatment decisions.
Assessment involves ctDNA analysis alongside tissue examination of ERBB2 and HER2 alterations.
Highlights the need for personalized treatment approaches based on biomarker evaluations in metastatic urothelial cancer.
Abstract
Supplementary Figure 6. Prognostic stratification of metastatic urothelial cancer (mUC) by ctDNA and tissue ERBB2/HER2 status and Eastern Cooperative Oncology Group (ECOG) performance status.